BS_47SJZ3PH
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 77.29960578186596
- age_years
- 15.356
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.486
- INTERFERON_GAMMA_RESPONSE+0.426
- IL6_JAK_STAT3_SIGNALING+0.420
- INTERFERON_ALPHA_RESPONSE+0.419
- COAGULATION+0.387
- ANDROGEN_RESPONSE+0.379
- COMPLEMENT+0.378
- ANGIOGENESIS+0.375
- PROTEIN_SECRETION+0.362
- BILE_ACID_METABOLISM+0.357
Top 10 suppressed
- E2F_TARGETS-0.457
- G2M_CHECKPOINT-0.452
- MYC_TARGETS_V2-0.431
- MYC_TARGETS_V1-0.400
- OXIDATIVE_PHOSPHORYLATION-0.247
- DNA_REPAIR-0.230
- PANCREAS_BETA_CELLS-0.218
- UV_RESPONSE_UP-0.190
- WNT_BETA_CATENIN_SIGNALING-0.180
- SPERMATOGENESIS-0.169
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_BC936YNZ | pilocytic astrocytoma | — | 0.926 |
| 2 | BS_Z7Y2466H | pilocytic astrocytoma | — | 0.914 |
| 3 | BS_MY9D8XZ1 | pilocytic astrocytoma | — | 0.907 |
| 4 | SRR1346813 | GTEX | — | 0.904 |
| 5 | BS_2ADZNNV4 | pilocytic astrocytoma | — | 0.900 |
| 6 | BS_JWSR581E | low-grade glioma | — | 0.897 |
| 7 | BS_S4V9E1XJ | pilocytic astrocytoma | — | 0.893 |
| 8 | BS_F8N6CFQE | low-grade glioma | — | 0.889 |
| 9 | BS_AP0SZ364 | low-grade glioma | — | 0.889 |
| 10 | BS_4HQ3T2NC | pilocytic astrocytoma | — | 0.888 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.486 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.426 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.419 | Inavolisib | — uncovered |
| COAGULATION | 0.387 | Binimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.379 | Inavolisib | — uncovered |
| COMPLEMENT | 0.378 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.375 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.362 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.357 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.357 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.348 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.348 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.339 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.317 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.293 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.291 | Inavolisib | — uncovered |
| APOPTOSIS | 0.234 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.225 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.222 | Inavolisib | — uncovered |